

# INTEGRATED PROTEINS LIMITED

Manek Centre, Office No 218, P N Marg, Jamnagar – 361008, Gujarat, India

Email ID: [integrated.pl2024@gmail.com](mailto:integrated.pl2024@gmail.com)

Website: [www.integratedproteins.com](http://www.integratedproteins.com)

CIN: L62013GJ1992PLC018426

---

Date: 12<sup>th</sup> February, 2026

To,  
BSE Limited  
Phiroz Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

Ref : Scrip Code - 519606

**Sub: Outcome of the meeting of the Board of Directors held on Thursday, 12<sup>th</sup> February, 2026 pursuant to regulation 30 & 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulation, 2015.**

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30 (read with Part A of Schedule II) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), and in continuation to our letter dated 7th February, 2026, we hereby report the outcome of the meeting of the Board of Directors held today, ie: Thursday, 12th February, 2026, inter-alia, to consider and approve the following:

1. Considered and approved the Unaudited Financial Results for the Quarter and Nine Months ended on 31<sup>st</sup> December, 2025 along with the Limited Review Report by the auditors.
2. Reviewed business of the Company.

The Board meeting commenced at 04:30 PM and ended at 05:00 PM. You are requested to take above on your records. Thanking you in anticipation.

For and on behalf of  
INTEGRATED PROTEINS LIMITED

---

KARANJ DHARMESHBHAI DOSHI  
DIN:10848249  
MANAGING DIRECTOR

# INTEGRATED PROTEINS LIMITED

CIN: L62013GJ1992PLC018426

Office No. 218, Manek Centre, Pandit Nehru Marg, Patel Colony, Jamnagar, Jamnagar, Gujarat, India, 361008

Website: www.integratedproteins.com

Statement of Unaudited Standalone Financial Results for the Quarter and Nine month ended December 31, 2025


(Rs. In Lakh except EPS)

Particulars	Quarter Ended			Nine Month Ended		For The Year Ended
	31/12/2025	30/09/2025	31/12/2024	31/12/2025	31/12/2024	31/03/2025
A Date of start of reporting period	01/10/2025	01/07/2025	01/10/2024	01/04/2025	01/04/2024	01/04/2024
B Date of end of reporting period	31/12/2025	30/09/2025	31/12/2024	31/12/2025	31/12/2024	31/03/2025
C Whether results are audited or unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>Revenue From Operations</b>						
(a) Revenue From Operations	-	419.82	0.96	424.54	0.96	2,149.63
(b) Other Income	-	-	11.81	-	19.85	23.74
<b>Total Revenue from operations (net)</b>	-	<b>419.82</b>	<b>12.77</b>	<b>424.54</b>	<b>20.81</b>	<b>2,173.37</b>
<b>Expenditure</b>						
(a) Cost of materials consumed	-	-	-	-	-	-
(b) Purchases of stock-in-trade	-	404.45	-	404.45	-	2,102.50
(c) Changes in inventories of finished goods, work-in- progress and stock-in-trade	-	-	-	-	-	-
(d) Employee benefit expense	0.60	1.35	0.31	2.62	1.63	1.63
(e) Finance Costs	-	2.08	-	-	-	-
(e) Depreciation and amortisation expense	-	-	-	-	0.96	0.96
(f) Other Expenses	0.95	5.22	4.40	14.35	13.68	36.33
<b>Total expenses</b>	<b>1.55</b>	<b>413.10</b>	<b>4.71</b>	<b>421.41</b>	<b>16.27</b>	<b>2,141.42</b>
<b>Profit (loss) Before exceptional &amp; Extraordinary items and Tax</b>	<b>(1.55)</b>	<b>6.72</b>	<b>8.06</b>	<b>3.13</b>	<b>4.54</b>	<b>31.94</b>
Exceptional items						
<b>Profit (loss) from ordinary activities before tax</b>	<b>(1.55)</b>	<b>6.72</b>	<b>8.06</b>	<b>3.13</b>	<b>4.54</b>	<b>31.94</b>
Tax Expenses - Current Tax	-	1.69	1.14	-	1.14	8.04
(less):- MAT Credit	-	-	-	-	-	-
Current Tax Expense Relating to Prior years	-	-	-	-	-	-
Deferred Tax (Assets)/Liabilities	-	-	-	-	-	(1.10)
<b>Profit (loss) from ordinary activities</b>	<b>(1.55)</b>	<b>5.03</b>	<b>6.92</b>	<b>3.13</b>	<b>3.40</b>	<b>25.00</b>
<b>Other Comprehensive Income (OCI)</b>						
Items that will not be reclassified to profit or loss						
Income tax relating to items that will not be reclassified to profit or loss						
Items that will be reclassified to profit or loss						
Income tax relating to items that will be reclassified to profit or loss						
<b>Total Profit After Other Comprehensive Income</b>	<b>(1.55)</b>	<b>5.03</b>	<b>6.92</b>	<b>3.13</b>	<b>3.40</b>	<b>25.00</b>
Profit/(Loss) From Discounting Operation Before Tax						
Tax Expenses of Discounting Operations						
<b>Net Profit/(Loss) from Discounting Operation After Tax</b>						
<b>Profit(Loss) For Period Before Minority Interest</b>						
Share Of Profit / Loss Associates						
Profit/Loss Of Minority Interest						
<b>Net Profit (+) / Loss (-) For the Period</b>	<b>(1.55)</b>	<b>5.03</b>	<b>6.92</b>	<b>3.13</b>	<b>3.40</b>	<b>25.00</b>
<b>Details of equity share capital</b>						
Paid-up equity share capital	320.36	320.36	352.02	320.36	352.02	320.36
Face value of equity share capital (per share)	10.00	10.00	10.00	10.00	10.00	10.00
Reserve Excluding Revaluation Reserves As Par Balance sheet of previous Year	-	(29.39)	-	-	-	(34.43)
<b>Earnings per share (EPS)</b>						
Basic earnings per share from countinuing And Discountinuing operations	(0.05)	0.16	0.20	0.10	0.10	0.78
Diluted earnings per share from countinuing And Discountinuing operations	(0.05)	0.16	0.20	0.10	0.10	0.78

**Notes:-**

- 1 The above said financial results were reviewed by the Audit Committee and then approved by the Board of Directors at their respective Meetings held on 12th February, 2026.
- 2 The Statutory Auditors have carried out limited review of the Unaudited Results of the Compnay for the Quarter and Nine Month ended 31/12/2025.
- 3 These results have been prepared in accordance with the Indian Accounting Standard (referred to as "Ind AS") 34 - Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules as amended from time to time.
- 4 The Company has no reportable business segment. Hence, separate information for segment wise disclosure is given in accordance with the requirements of Ind AS (AS) 108 - "Segment Reporting" is not required.
- 6 The figures for the corresponding previous period have been regrouped/ reclassified wherever necessary, to make them comparable.

Date :- 12/02/2026  
Place:- Jamnagar



For, INTEGRATED PROTEINS LIMITED

*Karanj Doshi*

KARANJ DOSHI  
Managing Director  
DIN:10848249



# INTEGRATED PROTEINS LIMITED

Manek Centre, Office No 218, P N Marg, Jamnagar – 361008, Gujarat, India

Email ID: [integrated.pl2024@gmail.com](mailto:integrated.pl2024@gmail.com)

Website: [www.integratedproteins.com](http://www.integratedproteins.com)

CIN: L62013GJ1992PLC018426

## Annexure-A

(Rupees in lakhs)

Statement on deviation / variation in Utilization of funds raised						
Name of listed entity		Integrated Proteins Limited				
Mode of Fund Raising	Public Issues / Rights Issues / Preferential Issues	Preferential Issue				
Date of Raising Funds	24/01/2025, 28/01/2025, 01/02/2025, 03/02/2025 & 04/02/2025					
Amount Raised	Rs 1744.88 lakhs					
Report filed for Quarter ended	December-25					
Monitoring Agency	applicable / not applicable	N.A.				
Monitoring Agency Name, if applicable	N.A.					
Is there a Deviation / Variation in use of funds raised	Yes / No	No				
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	N.A.					
If Yes, Date of shareholder Approval	N.A.					
Explanation for the Deviation / Variation	N.A.					
Comments of the Audit Committee after review	N.A.					
Comments of the auditors, if any	Nil					
Objects for which funds have been raised and where there has been a deviation, in the following table						
Original Object	Modified Object, if any	Original Allocation (Rupees in lakhs)	Modified allocation, if any	Funds Utilized (Rupees in lakhs)	Amount of Deviation/ Variation for the quarter according to applicable object	Remarks if any
The proceeds of the Preferential Issue shall be utilized for capital expenditure, acquisition in the same line of business, repayment of borrowings of the Company, expansion plans including investments in subsidiaries, working capital requirement, exploring new initiatives, meeting future funding requirements, general corporate purposes and such other purpose as the Board may decide.	N.A.	1)Rs. 1054.75 lakhs for capital expenditure 2)Rs. 690.13 lakhs For exploring new initiatives	N.A.	Rs. 1744.88 lakhs	N.A.	N.A.
Deviation or variation could mean: (a) Deviation in the objects or purposes for which the funds have been raised or (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or (c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc						
For, Integrated Proteins Limited						
Karanj Dharmeshbhai Doshi Managing Director DIN: 10848249						



**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Review Report to**  
**The Board of Directors**  
**INTEGRATED PROTEINS LIMITED**

We have reviewed the accompanying statement of unaudited financial results of **INTEGRATED PROTEINS LIMITED** (the "Company") for the quarter and nine month ended December 31, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that





**B.B. Gusani & Associates**  
**Chartered Accountants**

**CA BHARGAV B. GUSANI**  
M bhargavgusani77@gmail.com

we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For, B B Gusani and Associates**  
**Chartered Accountants**



**Bhargav B Gusani**

**Proprietor**

**Membership No. 120710**

**FRN: 140785W**

**UDIN: 26120710YBYPHN1071**

**Date: 12/02/2026**

**Place: Jamnagar**

**Office Address: 215, Manek Center, P.N. Marg,  
Jamnagar - 361008. (Gujarat) India**